title: The Utility of Impulsive Bias and Altered Decision Making as Predictors of Drug Efficacy and Target Selection: Rethinking Behavioral Screening for Antidepressant Drugs.
abstract: Cognitive dysfunction may be a core feature of major depressive disorder, including affective processing bias, abnormal response to negative feedback, changes in decision making, and increased impulsivity. Accordingly, a translational medicine paradigm predicts clinical action of novel antidepressants by examining drug-induced changes in affective processing bias. With some exceptions, these concepts have not been systematically applied to preclinical models to test new chemical entities. The purpose of this review is to examine whether an empirically derived behavioral screen for antidepressant drugs may screen for compounds, at least in part, by modulating an impulsive biasing of responding and altered decision making. The differential-reinforcement-of-low-rate (DRL) 72-second schedule is an operant schedule with a documented fidelity for discriminating antidepressant drugs from nonantidepressant drugs. However, a theoretical basis for this empirical relationship has been lacking. Therefore, this review will discuss whether response bias toward impulsive behavior may be a critical screening characteristic of DRL behavior requiring long inter-response times to obtain rewards. This review will compare and contrast DRL behavior with the five-choice serial reaction time task, a test specifically designed for assessing motoric impulsivity, with respect to psychopharmacological testing and the neural basis of distributed macrocircuits underlying these tasks. This comparison suggests that the existing empirical basis for the DRL 72-second schedule as a pharmacological screen for antidepressant drugs is complemented by a novel hypothesis that altering impulsive response bias for rodents trained on this operant schedule is a previously unrecognized theoretical cornerstone for this screening paradigm.
authors.affiliation: Astellas Pharma Development, Northbrook, Illinois (G.J.M.); Alexion Pharmaceuticals, Cheshire, Connecticut (M.D.); and AbbVie, North Chicago. Illinois (T.J.H.) gerard.marek@astellas.com.
authors.forename: Gerard J
authors.initials: GJ
authors.lastname: Marek
authors.affiliation: Astellas Pharma Development, Northbrook, Illinois (G.J.M.); Alexion Pharmaceuticals, Cheshire, Connecticut (M.D.); and AbbVie, North Chicago. Illinois (T.J.H.).
authors.forename: Mark
authors.initials: M
authors.lastname: Day
authors.affiliation: Astellas Pharma Development, Northbrook, Illinois (G.J.M.); Alexion Pharmaceuticals, Cheshire, Connecticut (M.D.); and AbbVie, North Chicago. Illinois (T.J.H.).
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Hudzik
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage*; D003657:Decision Making; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy*; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000639:trends; D006801:Humans; D007175:Impulsive Behavior; D011237:Predictive Value of Tests; D012055:Reinforcement Schedule; D013850:Thinking; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents